News INmune Bio slumps on midstage fail for Alzheimer's drug INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.
News Biogen races into phase 3 with Spinraza follow-up Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.
News Welsh biotech Draig emerges with $140m in financing Draig Therapeutics emerged from the shadows this morning with $140m in funding and a quest to develop new therapies for neuropsychiatric diseases.
News NewAmsterdam says lead drug may have Alzheimer's role NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.
News Sanofi makes Alzheimer's play with Vigil takeover Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.
News Alzheon Alzheimer's hopes dented by trial readout Alzheon has been left sifting through data from a failed Alzheimer's trial for crumbs of evidence that its oral therapy may have some efficacy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
